| HOME >> BIOLOGY >> TECHNOLOGY |
and Scandinavia (includes corresponding Graph/Chart) III-24
Europe Lacks R&D Innovation in Bladder Cancer Market III-24
Focus on Select Regional Market III-24
United Kingdom III-24
Bladder Cancer Prevalence - A Review III-24
Bladder Cancer Statistics in the UK III-25
Table 23: Incidence, Mortality, and Five-Year Survival
Rate of Bladder Cancer in UK by Gender: 2006 III-25
Table 24: Bladder Cancer Incidence by Region (2006) for
England, Wales, Scotland, and Northern Ireland (includes
corresponding Graph/Chart) III-25
Table 25: Age-Specific Incidence of Bladder Cancer by
Gender: 2006 (includes corresponding Graph/Chart) III-25
Table 26: Number of Bladder Cancer Deaths in the UK
(2007): Breakdown by Region - England, Wales, Scotland,
and Northern Ireland (includes corresponding Graph/Chart) III-26
Table 27: Age-Specific Bladder Cancer Mortality Rate in UK
Males: Breakdown by Age Group for 2007 (includes
corresponding Graph/Chart) III-26
Table 28: Age-Specific Bladder Cancer Mortality Rate in UK
Females: Breakdown by Age Group for 2007 (includes
corresponding Graph/Chart) III-26
Strategic Corporate Developments III-26
Select Players III-28
Affitech A/S (Denmark) III-28
Astrazeneca PLC (UK) III-28
BioCis Pharma Ltd (Finland) III-29
Cambridge Laboratories Ltd. (UK) III-29
curasan AG (Germany) III-29
Cytavis BioPharma GmbH (Germany) III-29
ENKAM Pharmaceuticals A/S (Denmark) III-30
F. Hoffmann-La Roche Ltd. (Switzerland) III-30
Laboratoires Pierre Fabre SA (France) III-30
NatImmune A/S (Denmark) III-31
Sanofi-Aventis (France) III-31
Telormedix SA (Switzerland) III-32
B.Market Analytics III-33
Table 29: European Recent Past, Current and Future Analysis
for Bladder Cancer Therapeutics - Annual Revenues
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |